Tarsus Pharmaceuticals, Inc.

Good afternoon and welcome to TARCIS 3rd Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded and all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. At this time, I would like to turn the call over to David Nakasone, Head of Investillations, to lead off the call. David, you may begin.

Thank you. Before we begin, I encourage everyone to visit the investor section of the Tarsus website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Madawala, our Chief Commercial Officer, and Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. With that, I will turn the call over to Bobby.

Good afternoon, and thank you for joining us. This quarter, Tarsus delivered exceptional results that continue to raise the bar for what a successful product launch looks like. Xtemvi is now one of the best-selling prescription eye drops in the market, setting a new benchmark for launch performance across the pharmaceutical industry. We delivered more than 103,000 bottles of Xtemvi to patients and recognized approximately $119 million in net revenue. These results reflect the strength of our category-creating blueprint, the increasing physician engagement, and the profound impact we are having on patients. What's more, we strongly believe we are just scratching the surface on the full potential of this launch. More than 20,000 doctors have already prescribed Xtemvi. And once they see successful patient outcomes, they start proactively looking for more patients they can help, broadening utilization across multiple patient segments and bringing us closer to our goal of serving millions of patients. Not only are we seeing this in the numbers, we hear it directly from eye care professionals, or ECPs. Recently, I was at two of the most impactful medical meetings in eye care, the American Academy of Optometry and the American Academy of Ophthalmology. Three key themes stood out. First, ECPs consistently described Xtemvi as one of the most meaningful therapeutic advances in eye care in decades. Second, Even our top prescribers say they haven't come close to reaching their full potential. And third, doctors are changing their practice patterns and broadening their use of Xtembe across a wider range of patients, particularly in light of our recent meibomian gland disease data in demonex blepharitis patients. That data has been a catalyst for them to look more proactively for demonex blepharitis or DB across patients coming in for complementary conditions like dry eye, cataracts, and contact lens intolerance. That third point hits very close to home, as both of my parents were prescribed Xtemvi after recent visits for two different conditions. My dad came in for a cataract surgery and my mom with a STI. During their visits, they were both diagnosed with DB. This expanding clinical recognition is being further amplified by our direct-to-consumer or DTC efforts which are bringing new patients into offices, many of whom are asking for ExtenV by name. With patients proactively asking to be screened for DB, broad access, and a best-in-class platform in Salesforce, these strong tailwinds are propelling the next frontier of growth, and we are just getting started. Aziz and Jeff will share more proof points later in the call. But suffice it to say, we are very pleased with the ongoing depth of adoption across multiple DB patient segments. Turning to our pipeline, the progress we've built with ExtenV gives us tremendous confidence in the trajectory of our next potential category creating opportunity, ocular rosacea. This is yet another area of uncharted territory that ECPs emphatically told us was a significant area of unmet need. Listening and working closely with ECPs to fully understand the needs of the patients has been foundational to our success at Tarsus, and that partnership is guiding the design of our Phase II trial, which we plan to initiate by year's end. Additionally, we see ample opportunity to expand globally, including in Europe and Japan, and to advance our Lyme disease prevention program, which represents yet another opportunity for category creation. We have built remarkable momentum, and as you will hear from Jeff, we continue to outperform the eye care market, and we believe Tarsus is positioned to become the next leader in eye care. I am so proud of our team for setting a new standard in treating demonyx blepharitis, and we're applying that same innovation mindset to conditions that have been underserved for far too long. We know what it takes to create a market, shift behavior, and deliver long-term value, and this is just the beginning. As we look ahead into 26 and beyond, we expect this powerful momentum to carry forward as we continue to expand our pipeline and increase our impact, setting us up for years of potential tremendous growth. With that, I'll now turn the call over to Aziz. Thanks, Bobby.